MYZAP

Across TCGA pan-cancer cohorts, MYZAP RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated MYZAP data layer compared with 5 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MYZAP RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MYZAP expression acts as an unfavorable survival marker, although some lineages such as BLCA and BRCA show a favorable association.

OV, LUSC, and LGG are the cancer types where MYZAP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.789	0.889	<.001	78	view →
LUSC	DFS	Median	All	0.293	0.461	<.001	65	view →
LGG	OS	Median	All	0.723	0.895	<.001	53	view →
CESC	DFS	Median	III,IV	0.147	0.612	<.001	48	view →
BLCA	OS	Quartile	All	0.804	0.639	.002	38	view →
BRCA	OS	Tertile	III,IV	0.973	0.867	.002	36	view →
MESO	DFS	Tertile	IV	0.688	0.173	.001	34	view →
THCA	DFS	Median	All	0.949	0.861	.001	24	view →
ESCA	DFS	Median	II,III,IV	0.293	1.000	.002	19	view →
UCEC	DFS	Quartile	IV	0.169	0.755	.002	12	view →
READ	DFS	Tertile	IV	0.380	0.806	.006	10	view →
LIHC	OS	Quartile	II,III,IV	0.453	0.691	.021	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

MYZAP–OV (OS)

Open the OV breakdown →